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Background: Psoriasis is an immune-mediated, chronic in-
flammatory disease affecting multiple aspects of patients’ 
lives. Its epidemiology varies regionally; however, nation-
wide epidemiologic data on psoriasis depicting profile of 
Korean patients has not been available to date. Objective: To 
understand nationwide epidemiologic characteristics and 
clinical features of adult patients with psoriasis visited uni-
versity hospitals in Korea. Methods: This multicenter, non-in-
terventional, cross-sectional study recruited 1,278 adult pa-
tients with psoriasis across 25 centers in Korea in 2013. 
Various clinical data including PASI, BSA, DLQI, SF-36 and 
PASE were collected. Results: A total of 1,260 patients com-
pleted the study (male:female=1.47:1). The mean age was 
47.0 years with a distribution mostly in the 50s (24.9%). Early 
onset (＜40 years) of psoriasis accounted for 53.9% of 
patients. The mean disease duration was 109.2 months; 
mean body mass index was 23.9 kg/m2; and 12.7% of pa-
tients had a family history of psoriasis. Plaque and guttate 
types of psoriasis accounted for 85.8% and 8.4%, 
respectively. Patients with PASI ≥10 accounted for 24.9%; 
patients with body surface area ≥10 were 45.9%. Patients 
with DLQI ≥6 accounted for 78.8%. Between PASI ＜10 
and PASI ≥10 groups, significant difference was noted in 
age at diagnosis, disease duration, blood pressure, waist cir-
cumference of female, and treatment experiences with pho-
totherapy, systemic agents, and biologics. Conclusion: This 
was the first nationwide epidemiologic study of patients with 
psoriasis in Korea and provides an overview of the epidemio-
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logic characteristics and clinical profiles of this patient 
population. (Ann Dermatol 29(4) 462∼470, 2017)
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INTRODUCTION
Psoriasis is an immune-mediated, chronic inflammatory 
disease affecting various aspects of patients’ lives far be-
yond the skin and challenging clinicians in its manage-
ment1. While psoriasis is prevailing worldwide, there are 
regional differences in its epidemiological characteristics. 
Local differences in genetic, environmental, cultural, and 
geographic characteristics may be related. Although out-
standing progress have achieved in various fields of psor-
iasis research, understanding epidemiologic profiles of the 
disease is still important. A more elaborate understanding 
of regional epidemiology is essential to refining the man-
agement of psoriasis. Unlike many western countries, 
where data from many large-scale epidemiologic studies 
are available, epidemiologic study data of nationwide 
scale were unavailable in Korea. In 2013, the Korean 
Society for Psoriasis (KSP) conducted a cross-sectional, 
multicenter study to delineate the clinical profile of adult 
patients with psoriasis visiting university hospitals in 
Korea. Here we report the results of this study. 
MATERIALS AND METHODS 
Study design 
This was a multicenter, non-interventional, cross-sectional 
study. Patients were recruited for approximately 4 months, 
from February to June 2013. The 25 centers participating 
in the study were mainly university hospitals, located 
across the country (with the exception of the Jeju island 
region). This study was reviewed and approved by the 
Institutional Review Board of each center. To extract a 
representative sample reflecting the distribution of psor-
iasis in Korea, numbers and locations of study centers 
were selected on the basis of population distribution and 
health insurance reimbursement data of the patients with 
psoriasis in Korea. 
Because half of the total population of Korea lives near the 
capital, 13 of 25 centers were selected from the capital 
area. To avoid selection bias, study patients were exam-
ined and enrolled consecutively by visiting orders. After 
obtaining informed consent, all procedures of the study 
were performed on 1 day. The study patients were adult 
patients aged 20 or older diagnosed with psoriasis. 
Clinical data were collected by interviewing the patients 
on demographic factors (age, sex, height, weight, waist 
circumference, disease duration, age at diagnosis, family 
history in first-degree relative, drinking/smoking history, 
and both past and ongoing concomitant therapies). 
Physical examination for disease-severity measures (psoriasis 
area and severity index [PASI], body surface area [BSA]), 
morphological characteristics (clinical types and location) 
of psoriasis and blood pressure were carried out for all en-
rolled patients. Quality of life was evaluated by the derma-
tology life quality index (DLQI) and MOS 36-item short-form 
health survey (SF-36). Screening for psoriatic arthritis was 
done using the psoriatic arthritis screening and evaluation 
(PASE) tool. In addition, data on treatment-related factors 
(past and current treatment history, patient satisfaction for 
treatment) were collected. In order to evaluate patient sat-
isfaction for various therapies, questions from the Medication 
Satisfaction Questionnaire (MSQ)2, which is a validated 
tool for evaluating treatment satisfaction among patients 
with schizophrenia, were used in this study. Patients scor-
ed their response to the question, “In general, how sat-
isfied are you with your current treatment?” on a 7-point 
scale ranging from 1 to 7 (a score of 4 means neutral). 
Statistical analysis 
Descriptive statistics for continuous variables are pre-
sented as means with standard deviation, and dichoto-
mous variables are presented as frequencies with percen-
tages in parentheses. Types of psoriasis, location of in-
volved lesions, and clinical/demographic characteristics 
were compared to assess the statistical significance of any 
differences among the groups by disease severity (PASI 
＜10, PASI ≥10). We used, where appropriate, the 
Wilcoxon rank-sum and t tests for continuous variables, 
and analyses for dichotomous variables that were based 
on Pearson’s chi-square test and Fisher’s exact test, with-
out missing data imputation. In addition, a multiple logis-
tic regression analysis was used to assess the adjusted ef-
fect of characteristics on PASI ≥10. Multicollinearity be-
tween independent variables had been checked by com-
puting correlation coefficient and variance inflation factors 
(VIF) before the variables to be included in the regression 
model were selected. All statistical tests were performed 
using two-sided and p-values less than 0.05 were consid-
ered statistically significant. Analyses were performed us-
ing the statistical software package SAS 9.2 (SAS Institute, 
Cary, NC, USA). 
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Table 1. Demographics 
Characteristics Total Overall PASI＜10 PASI≥10 p-value
Gender 1,260 0.215
  Male 749 (59.4) 553 (58.5) 196 (62.4)
  Female 511 (40.6) 393 (41.5) 118 (37.6)
Age (yr) 1,260 47.0±14.5 47.3±14.3 46.3±15.0 0.310
Age at diagnosis (yr) 1,257 38.6±16.5 39.3±16.2 36.4±17.0 0.008*
  ＜40 677 (53.9) 492 (52.1) 185 (59.1)
0.032*
  ≥40 580 (46.1) 452 (47.9) 128 (40.9)
Disease duration (mo) 1,257 109.2±122.0 103.3±118.2 126.9±131.5 0.003*
Family history 1,260 160 (12.7) 128 (13.5)  32 (10.2) 0.124
Height (cm) 1,259 166.5±8.4 166.5±8.5 166.5±8.3 0.925
Weight (kg) 1,259 66.4±12.4 66.1±12.2 67.4±12.9 0.116
BMI (kg/m2) 1,259 23.9±3.5 23.8±3.4 24.2±3.8 0.059
  Male 748 24.5±3.2 24.5±3.1 24.6±3.5 0.699
  Female 511 23.0±3.7 22.8±3.5 23.6±4.2 0.046*
Waist circumference (cm) 1,113 84.3±11.1 83.8±11.0 85.6±11.4 0.022*
  Male (≥90 cm) 659 254 (38.5) 193 (38.6)  61 (38.4) 0.958
  Female (≥80 cm) 454 199 (43.8) 138 (40.0)  61 (56.0) 0.003*
SBP ≥140 mmHg or DBP ≥90 mmHg 1,164 231 (19.8) 158 (17.8)  73 (26.5) 0.001*
Smoking history 1,260 609 (48.3) 449 (47.5) 160 (51.0) 0.283
  Male 749 538 (71.8) 394 (71.2) 144 (73.5) 0.552
  Female 511  71 (13.9)  55 (14.0)  16 (13.6) 0.905
Drinking history 1,260 806 (64.0) 591 (62.5) 215 (68.5) 0.055
  Male 749 595 (79.4) 431 (77.9) 164 (83.7) 0.088
  Female 511 211 (41.3) 160 (40.7)  51 (43.2) 0.628
Values are presented as total number only, number (%), or mean±standard deviation. Total number does not always represent 100%
of the study population because of missing values. Percentages of subgroup (by gender) were based on the total number of subjects
in each PASI group per subgroup. PASI: psoriasis area and severity index, BMI: body mass index, SBP: systolic blood pressure, DBP:
diastolic blood pressure. *p-value＜0.05.
RESULTS 
Demographics 
A total of 1,278 patients were enrolled in the study, and 
1,260 (98.6%) completed the study. Eighteen patients 
(1.4%) were excluded from analysis, 16 (1.3%) for viola-
tion of the inclusion/exclusion criteria, and two (0.2%) for 
lack of data for the primary assessment. Demographic data 
from the 1,260 patients are presented in Table 1. A total of 
749 patients (59.4%) were male and 511 (40.6%) were fe-
male; the male to female ratio was 1.47:1. The mean age 
of the study patients was 47.0±14.5 years (range, 20∼89 
years). Most study patients were in their 50s (24.9%), with 
a gradual increase from 20s to 50s and a sharp decrease 
after 60s. The distribution pattern of age at diagnosis re-
vealed dual peaks at 21∼25 years and 46∼50 years (Fig. 
1). A ratio of early onset (＜40 years) versus late onset 
(≥40 years) at diagnosis was 53.9% versus 46.1% (33.8% 
versus 66.2% when divided by age of 30 years old). The 
mean disease duration was 109.2±122.0 months. Mean 
height and weight were 166.5±8.4 cm and 66.4±12.4 
kg, respectively, and mean body mass index (BMI) was 
23.9±3.5 kg/m2. At the time of the study, 48.3% (n=609) 
of the total patients had a history of smoking and 64.0% 
(n=806) had a history of drinking. Male showed higher 
rate in smoking/drinking history than female. Patients who 
had a family history of psoriasis in a first-degree relative 
accounted for 12.7% (n=160) of the total. 
Clinical type of psoriasis 
Plaque-type psoriasis was the most prevalent, occurring in 
1,081 patients (85.8%), followed by guttate type in 106 
(8.4%), pustular type (including localized form) in 66 
(5.2%), erythrodermic type in 44 (3.5%), annular type in 
24 (1.9%), and inverse type in 4 (0.3%) (Table 2). 
Location of lesions 
Psoriasis lesions were most frequently found in the lower 
leg (72.6%, n=913), followed by the back (60.9%, n=766), 
upper leg (60.8%, n=764), elbow (58.0%, n=729), knee 
(57.1%, n=718), lower arm (56.8%, n=714), abdomen 
(55.7%, n=700), upper arm (53.5%, n=672), and scalp 
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Fig. 1. Age distribution of patient (A) and distribution of age at diagnosis (B). 
Table 2. Types of psoriasis 
Classification Overall (n=1,260)
Plaque 1,081 (85.8)
Guttate 106 (8.4)
Pustular 66 (5.2)
Erythrodermic 44 (3.5)
Annular 24 (1.9)
Inverse  4 (0.3)
Values are presented as number (%).
Table 3. Location of involved lesions 
Classification
Overall 
(n=1,257)* 
PASI＜10 
(n=943)
PASI≥10 
(n=314)
Scalp 668 (53.1) 453 (48.0) 215 (68.5)
Face 349 (27.8) 218 (23.1) 131 (41.7)
Neck 205 (16.3) 104 (11.0) 101 (32.2)
Chest 536 (42.6) 334 (35.4) 202 (64.3)
Abdomen 700 (55.7) 460 (48.8) 240 (76.4)
Back 766 (60.9) 497 (52.7) 269 (85.7)
Upper arm 672 (53.5) 425 (45.1) 247 (78.7)
Elbow 729 (58.0) 484 (51.3) 245 (78.0)
Lower arm 714 (56.8) 462 (49.0) 252 (80.3)
Palm† 164 (13.0) 115 (12.2)  49 (15.6)
Back of hand 295 (23.5) 178 (18.9) 117 (37.3)
Nail 155 (12.3) 89 (9.4)  66 (21.0)
Upper leg 764 (60.8) 499 (52.9) 265 (84.4)
Knee 718 (57.1) 472 (50.1) 246 (78.3)
Lower leg 913 (72.6) 620 (65.7) 293 (93.3)
Foot sole† 146 (11.6) 103 (10.9)  43 (13.7)
Back of foot 217 (17.3) 127 (13.5)  90 (28.7)
Buttock 471 (37.5) 280 (29.7) 191 (60.8)
Genitalia 111 (8.8) 59 (6.3)  52 (16.6)
Other area†  8 (0.6)  4 (0.4)  4 (1.3)
Values are presented as number (%). PASI: psoriasis area and 
severity index. *3 patients are missing. †No significant p-value 
(other involved areas showed p-value＜0.0001).
(53.1%, n=668). Nail involvement was noted in 12.3% of 
patients and genitalia involvement in 8.8% of patients. 
Details of lesion location are listed in Table 3. 
Disease severity 
Of the total study patients, 75.1% (n=946) had PASI ＜10 
and 24.9% (n=314) scored PASI ≥10 (19.0% had 10≤
PASI＜20, 5.9% had PASI ≥20). The mean PASI score 
was 7.5±7.1. The mean BSA (%) measurement was 
13.1±14.6. 54.1% (n=681) of the total patients had BSA 
＜10, 45.9% (n=577) had BSA ≥10 (14.3% had BSA 
＜3%, 39.8% had 3≤BSA＜10, 25.4% had 10≤BSA
＜20, and 20.4% had BSA ≥20). On the other hand, with 
regards to the DLQI, results showed that of the 1,256 
study patients whose DLQI data were available, 21.2% 
(n=266) scored DLQI ≤5 (no/small effect), 24.7% (n=310) 
scored 6≤DLQI≤10 (moderate effect), and 54.1% (n=680) 
scored DLQI ≥11 (very/extremely large effect). The mean 
value of DLQI was 12.0±7.2 (Fig. 2). The mean SF-36 re-
sults were 48.8±8.0 for the physical component summary 
score and 42.6±11.2 for the mental component summary 
score (data not shown). PASE data were available for 
1,255 patients. The mean PASE score was 33.7±13.1; 
301 (24.0%) patients had a PASE score of 44 points or 
higher (Fig. 3). 
Past and concomitant therapies
Of all past therapies utilized by the study patients 
(n=1,260), topical agents were the most common (93.6%, 
n=1,179), followed by systemic agents (61.2%, n=771), 
phototherapy (50.8%, n=640), and biologics (5.7%, n=72). 
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Fig. 2. Disease severity classified by psoriasis area and severity index (PASI), body surface area (BSA), and dermatology life quality 
index (DLQI). Overall mean±standard deviation (SD) are presented below the title. Each n (%) of the classified group is presented. 
Fig. 3. Psoriatic arthritis screening and evaluation (PASE). SD: 
standard deviation.
The order of current therapy maintained at the time of en-
rollment was topical agent (86.0%, n=1,083), oral sys-
temic agents (45.9%, n=578), phototherapy (30.6%, 
n=385), and biologics (4.6%, n=58). Although herbal 
medicine was used at some point by a considerable num-
ber of patients, it was seldom maintained (Table 4).
Comparison of factors related to disease based on 
disease severity 
The patients were divided into two groups of PASI ＜10 
and PASI ≥10 and factors that could be related with dis-
ease severity were compared. Gender, age, family history, 
height and weight, smoking/drinking history, and male 
gender’s waist circumference and BMI did not showed 
any significant difference between two groups. However, 
there was significant difference between two groups re-
garding BMI in female, age at diagnosis, disease duration, 
waist circumference of female, blood pressure. The group 
with PASI ≥10 had longer disease duration (p=0.003) 
and earlier age of diagnosis (p=0.008) than the group 
with PASI ＜10 and comprised a significantly higher pro-
portion of patients with systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg (p=0.001). 
BMI in female was significantly higher (p=0.046) and the 
proportion of waist circumference with ≥80 cm in female 
was higher in PASI ≥10 group (p=0.003, Table 1). Most 
of body parts were involved more as disease severity in-
creased except for palm, sole (Table 3). After adjusting for 
variables in demographic characteristics except age at di-
agnosis, height and weight due to multicollinearity, younger 
age, longer disease duration, absence of family history, 
longer waist circumference and higher blood pressure 
were significantly associated with severe disease (PASI ≥
10, Table 5). More patients with PASI ≥10 had experi-
enced treatment with phototherapy, systemic agents, and 
biologics compared to patients with PASI ＜10 (Table 4). 
Treatment satisfaction 
Patients were divided into three treatment satisfaction 
groups: dissatisfied (from extremely dissatisfied to some-
what dissatisfied), neutral, or satisfied (from somewhat sat-
isfied to extremely satisfied). The satisfied group included 
733 patients (58.5%); neutral group, 317 (25.3%); and dis-
satisfied group, 202 (16.1%). In the PASI ＜10 group, sat-
isfied proportion was significantly higher than the PASI ≥
10 group (p=0.002, Table 6). 
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Table 5. Adjusted effect of characteristics on PASI ≥10 based on multiple logistic regression model (n=1,086) 
Characteristics Ref. OR 95% CI p-value
Gender Male 1.182 0.810∼1.725 0.386
Age 0.987 0.977∼0.998 0.020*
Disease duration 1.002 1.001∼1.003 0.002*
Family history No 0.571 0.361∼0.905 0.017*
BMI 0.992 0.943∼1.044 0.763
Waist circumference 1.018 1.001∼1.036 0.036*
SBP ≥140 mmHg or DBP ≥90 mmHg No 1.535 1.090∼2.162 0.014*
Smoking history No 1.006 0.705∼1.435 0.975
Drinking history No 1.061 0.758∼1.485 0.731
One hundred seventy-four patients with missing data were excluded from the logistic regression analysis. PASI: psoriasis area and
severity index, Ref.: reference for odds ratio, OR: odds ratio, CI: confidence interval, BMI: body mass index, SBP: systolic blood
pressure, DBP: diastolic blood pressure. *p-value＜0.05.
Table 4. Past and current therapies
Category
Overall (n=1,260) PASI＜10
(n=946)
PASI≥10
(n=314)
p-value
Past and current Current only 
Topical 1,179 (93.6) 1,083 (86.0) 884 (93.4) 295 (93.9) 0.753
  Glucocorticosteroid   937 (74.4) 774 (61.4) 697 (73.7) 240 (76.4) 0.333
  Calcipotriol/tacalcitol   986 (78.3) 893 (70.9) 746 (78.9) 240 (76.4) 0.367
Phototherapy   640 (50.8) 385 (30.6) 463 (48.9) 177 (56.4) 0.023*
  UVA/UVB   35 (2.8) 19 (1.5) 32 (3.4)  3 (1.0) 0.023*
  Narrowband UVB   564 (44.8) 338 (26.8) 404 (42.7) 160 (51.0) 0.011*
  Broadspectrum UVB   10 (0.8)  6 (0.5)  7 (0.7)  3 (1.0) 0.717
  PUVA (systemic)   42 (3.3) 26 (2.1) 31 (3.3) 11 (3.5) 0.847
Systemic agents   771 (61.2) 578 (45.9) 561 (59.3) 210 (66.9) 0.017*
  Fumaric acid esters   4 (0.3)  0 (0.0)  2 (0.2)  2 (0.6) 0.260
  Methotrexate   280 (22.2) 174 (13.8) 205 (21.7)  75 (23.9) 0.413
  Acitretin   300 (23.8) 185 (14.7) 206 (21.8)  94 (29.9) 0.003*
  Cyclosporine   366 (29.1) 221 (17.5) 253 (26.7) 113 (36.0) 0.002*
  Oral corticosteroid  100 (7.9) 26 (2.1) 79 (8.4) 21 (6.7) 0.345
Biologics   72 (5.7) 58 (4.6) 45 (4.8) 27 (8.6) 0.011*
  Adalimumab    6 (0.5)  4 (0.3)  5 (0.5)  1 (0.3) 1.000
  Etanercept   13 (1.0)  2 (0.2)  7 (0.7)  6 (1.9) 0.102
  Infliximab    7 (0.6)  5 (0.4)  5 (0.5)  2 (0.6) 0.687
  Ustekinumab   53 (4.2) 47 (3.7) 32 (3.4) 21 (6.7) 0.012*
Others   181 (14.4) 42 (3.3) 137 (14.5)  44 (14.0) 0.837
  Diet therapy   28 (2.2) 19 (1.5) 27 (2.9)  1 (0.3) 0.008*
  Herbal medicine  106 (8.4)  9 (0.7) 81 (8.6) 25 (8.0) 0.740
  Exercise therapy    8 (0.6)  8 (0.6)  7 (0.7)  1 (0.3) 0.688
  Spa   14 (1.1) 11 (0.9) 11 (1.2)  3 (1.0) 1.000
  Supplements   13 (1.0)  9 (0.7) 10 (1.1)  3 (1.0) 1.000
None   19 (1.5) - 18 (1.9)  1 (0.3) 0.058
Values are presented as number (%). PASI: psoriasis area and severity index, UV: ultraviolet, PUVA: psoralen and ultraviolet A.
*p-value＜0.05. 
DISCUSSION 
Prior to this study, epidemiologic data for the patients with 
psoriasis in Korea were limited to small-scale or sin-
gle-center studies using accumulated patient pools over 
long periods of time3. For this reason, it was difficult to ob-
tain an overview of nationwide epidemiologic profile of 
psoriasis that is necessary for further research and better 
policy making for the patients with psoriasis in Korea. 
Hence, the KSP designed and conducted a nationwide 
HJ Song, et al
468 Ann Dermatol
Table 6. Comparing the degree of satisfaction with treatment
Category Overall (n=1,252)* PASI＜10 (n=939) PASI≥10 (n=313) p-value
Degree of satisfaction 　　 　　 　　 0.002†
  Extremely satisfied 42 (3.4) 34 (3.6) 8 (2.6) 　
  Very satisfied 229 (18.3) 192 (20.4) 37 (11.8)
  Somewhat satisfied 462 (36.9) 350 (37.3) 112 (35.8)
  Neutral 317 (25.3) 226 (24.1) 91 (29.1)
  Somewhat dissatisfied 125 (10.0) 89 (9.5) 36 (11.5)
  Very dissatisfied 58 (4.6) 36 (3.8) 22 (7.0)
  Extremely dissatisfied 19 (1.5) 12 (1.3) 7 (2.2)
Values are presented as number (%). PASI: psoriasis area and severity index. *8 patients are missing. †p-value＜0.05.
study in 2013 to delineate the epidemiologic profile of 
Korean patients with psoriasis. To minimize regional sam-
pling bias and improve temporal focusing, we matched 
the number and location of study centers with general 
population distribution data. As a result, the distributed 
proportion of recruited patients was very similar to that of 
the distributed proportion of claims for psoriasis in the 
Health Insurance Review and Assessment (HIRA) database 
of 2013. 
The mean age of patients in our study (47.0 years) was 
higher than that observed in hospital based Japanese stud-
ies (45.5 years4 and 44.7 years5) as well as a Chinese pop-
ulation-based study (41.8 years6), but was similar to a 
Taiwanese cohort study (46.4 years7). Unlike classical bi-
modal peaks in distribution patterns of age at diagnosis in 
western studies, which showed peaks located in the late 
teens and late 50s, Asian studies4,6, including ours, showed 
dual peaks located in the 20s and 40s. Additionally, ear-
ly-onset (type 1, ＜40 years) psoriasis accounted for more 
than 75% of patients in western studies8 and 67.6% of pa-
tients in the Chinese study6, but only 53.9% in our study. 
The prevalence of psoriasis has been reported to be equal 
between men and women in western studies9-11. However, 
in Asian studies4,5,7,12, male predominance has been re-
ported repeatedly. Our study also revealed the predom-
inance of this disease in males (male to female ratio 
1.47:1). This tendency was also noted in data from the 
Korean health insurance database in 2012 (1.36:1). But 
the degree of male predominance was somewhat lower 
than studies from other Asian countries such as Japan and 
Taiwan, which reported a male to female ratio of 1.6∼
2.1:15,7. Although this phenomenon may be unique to the 
study population, the cause of this interesting observation 
needs to be elucidated. 
Although it is well known that obesity is closely related to 
psoriasis in western populations8,13,14, the mean BMI of 
23.9±3.5 kg/m2 noted in our study was considerably low-
er than the mean BMI of 28.0 kg/m2 observed in western 
populations13. In addition, Kim and Lee15 reported no stat-
istical difference in BMI between the patients with psor-
iasis and a control group in one study of a Korean 
population. This implies that further research is necessary 
to clarify the association between obesity and psoriasis in 
the Korean population. 
Plaque-type psoriasis was the predominant clinical type in 
Korea, consistent with observations in Caucasian and oth-
er Asian populations5,16-18. Interestingly, although the pro-
portion of plaque psoriasis is similar, the proportion of 
guttate psoriasis is relatively high in Korean patients com-
pared with Japanese patients (8.4% versus 2.8%/3.9%)4,5. 
It was difficult to compare the involved site with other 
published studies, as each uses different criteria to dis-
tinguish the location in the body. For future studies, it is 
necessary to define the boundary of anatomical regions in 
a standardized manner and use common protocol to ex-
press involved areas. Hernánz et al.19 reported that pa-
tients with more severe psoriasis had greater skin involve-
ment in most of area including the palms and soles. 
However, our data showed no significant differences in 
the involvement of palms and soles by disease severity 
divided by PASI score 10. 
When comparing disease severity as measured by PASI 
and BSA with quality of life as measured by DLQI, it was 
found that the impact of psoriasis on quality of life was not 
fully explained by the severity or extent of skin disease. 
Therefore, an independent assessment of quality of life 
should be considered in the management of psoriasis. 
Some studies20,21 reported a higher disease severity in 
male patients than in female patients. Although there was 
a higher proportion of males in the severe group, it was 
not statistically significant in our study (p=0.215). 
Smoking has been known to be associated with the clin-
ical severity of psoriasis22 but the ratio of smoking history 
between two groups by disease severity did not differ 
statistically. Some studies have reported that patients with 
more severe disease had an earlier age of onset and a lon-
EPI-PSODE Study
Vol. 29, No. 4, 2017 469
ger disease duration19,23. Those results are in line with our 
findings. The more severe group presented with sig-
nificantly higher blood pressure, as reported by Cohen et 
al.24. 
Interestingly, the patients with family history showed sig-
nificantly milder disease severity than the patients without 
family history after adjusting for relevant demographic 
characteristics. Although there are some studies25,26 that 
family history is associated with early onset age, but it was 
difficult to find a study to explain a relationship between 
family history and disease severity. However, López-Este-
baranz et al.27 recently presented that the severity of psor-
iasis was not affected by the presence of a family history. 
Therefore, further studies are necessary to determine the 
association between family history and disease severity. 
Finally, it was remarkable that significantly more patients 
in the PASI ≥10 group were dissatisfied with treatment re-
sults than the PASI ＜10 group. This result indicates that 
more effective and satisfactory treatment is needed for pa-
tients with PASI ≥10. 
Although we attempted to minimize the bias from regional 
and temporal factors and reveal multilateral aspects of the 
clinical profiles of Korean patients with psoriasis, due to 
the recruitment of adult patients mostly from university 
hospitals, the representation of the general psoriasis pop-
ulation in Korea is limited. Further, because this study was 
cross-sectional, it is necessary to use caution when inter-
preting results for causal relationships between dis-
ease-related factors and outcomes over time. Therefore, 
additional research in the form of prospective longitudinal 
cohort studies is needed to further understanding of psor-
iasis in the Korean population. 
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